Generic Name and Formulations:
Liraglutide [rDNA origin] 6mg/mL; soln for SC inj.
Indications for VICTOZA:
As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.
Limitations Of use:
Not recommended as first-line treatment for patients inadequately controlled on diet and exercise. Not a substitute for insulin. Not for treating type 1 diabetes or ketoacidosis. Not studied in combination with prandial insulin or with a history of pancreatitis.
Give by SC inj in abdomen, thigh, or upper arm once daily. Initially 0.6mg/day for 1 week, then 1.2mg/day; may increase to 1.8mg/day. If >3 days elapsed since last dose, reinitiate at 0.6mg/day, then titrate. Renal impairment: caution with initiating or escalating doses.
<18yrs: not recommended.
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. Discontinue if pancreatitis is suspected; do not restart if confirmed. History of pancreatitis: consider other antidiabetic therapies. Do not reuse or share pens or needles between patients. Renal or hepatic impairment. Gastroparesis. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant insulin (insufficient data); administer as separate injections not adjacent to each other. Hypoglycemia with sulfonylureas or insulin (consider reducing their doses). May affect absorption of other drugs (delayed gastric emptying). Monitor digoxin.
Glucagon-like peptide-1 [GLP-1] receptor agonist.
Headache, nausea, diarrhea, antibody formation, immunogenicity reactions (eg, urticaria), constipation; rare: pancreatitis (discontinue if occurs), papillary thyroid carcinoma, anaphylactic reactions and angioedema (discontinue if occurs).
Multi-dose, pre-filled pen (3mL)—2, 3
- 3 pens of 18mg/3ml cartons (Qty:1)
- appx. price $661.00